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Cervical Cytology Versus Primary HPV Testing as Screening Tests for Cervical
Dysplasia
Biniam Abraham, PA-S; Erin Shea, PA-S
James Madison University

Abstract:
Background Cervical cancer is the fourth most common cancer among women,
accounting for 10% of all female cancers and 7.5% of all cancer deaths worldwide. 1,2
Human papillomavirus (HPV) has been detected in up to 99.7% of cervical cancers,
making it the primary risk factor for the development of cervical cancer.3 Current
guidelines recommend a screening test which includes a combination of cervical
cytology as well as HPV co-testing in women over the age of 30, with HPV testing not
recommended in women younger than the age of 30.11 The Food and Drug
Administration has approved primary HPV testing as a screening test for cervical
cancer, however this practice has not yet been adopted by the United States.
Continuing to use both methods for screening purposes may lead to discrepant results
which can be confusing for both the patient and the provider.12
Objective To determine the diagnostic efficacy of cervical cytology versus primary HPV
testing as screening tests for cervical dysplasia
Methods A Scopus and Pubmed search was conducted using the following search
terms and filters: “HPV screening versus cytology NOT home,” “within 5 years,” “full test
article” and “English.” Articles were screened and assessed for eligibility based on study
design, sample size, year of publication, participant characteristics, and study
objectives. Three articles were chosen for review.
Conclusion
Primary HPV testing may increase accuracy of referral for colposcopy and therefore
cervical intraepithelial neoplasia (CIN2+) diagnoses as compared to cytology. However,
these conclusions are based on diagnosis rates after colposcopy referral and therefore
do not address possible false-negative screening results in patients who have non-HPV
related lesions at the time of screening. Currently, there are also no clinical or
pathologic features that may guide clinicians in determining which patients may present
with false-negative screening results. Further study can focus on addressing this group
of patients that may present with false-negative HPV results at the time of screening.
Abbreviations and Acronyms:
HPV
human papillomavirus
HR-HPV high risk-human papillomavirus
CIN
cervical intraepithelial neoplasia
Pap
papanicolaou
LBC
liquid based cytology
HC2
hybrid capture 2
PCR
polymerase chain reaction
OB
obstetrics
ASCUS atypical squamous cells of undetermined significance
LSIL
low-grade squamous intraepithelial lesions
LA PCR linear chain polymerase chain reactions
HSIL
high-grade squamous intraepithelial lesions
OHR
other ‘high risk’
DS
dual stained
NILM
negative for intraepithelial lesion or malignancy

Introduction:
Cervical cancer is the fourth most common cancer among women, accounting for
10% of all female cancers and 7.5% of all cancer deaths worldwide. 1,2 Human
papillomavirus (HPV) has been detected in up to 99.7% of cervical cancers, making it
the primary risk factor for the development of cervical cancer.3 HPV infection is very
common with an estimated life-time risk of 80% in the general population. The highest
incidence of infection occurs in young women, at the mean age of 25 years old. The
prevalence of high-risk HPV infection (HR-HPV) in this age group can be as high as
60%.4 Approximately 70-90% of HPV infections remain asymptomatic and resolve within
1-2 years without intervention.5 Those who cannot resolve the infection spontaneously
may go on to develop high-grade cervical neoplasia due to persistent active infection
which may occur decades after initial exposure. Due to this active infection, there may
be continued cell activation along with loss of p53 tumor suppressor gene. The loss of
p-53 mediated DNA repair may lead to mutations in the normal genome which can
progress to cancer.4
The progression from high grade cervical dysplasia within the epithelial cells of
the uterine cervix to cancer is a long process. Cervical cancer can be divided into two
different histotypes: squamous cell carcinoma which is responsible for 70% of cervical
cancers and adenocarcinoma which is responsible for 15-20% of cervical cancers.
Squamous cell carcinoma develops through precursor cells called cervical intraepithelial
neoplasia (CIN), with the neoplastic cells being classified as 1-3, with 1 being mild and 3
being severe dysplasia. There is less known information regarding any precursor cells
for adenocarcinoma.6
There are 200 different genotypes of HPV and the International Agency for
Research on Cancer states there are 12 genotypes that are carcinogenic to humans,
with genotypes 16 and 18 being having the highest association with high grade cervical
intraepithelial neoplasia and the two most frequent genotypes leading to cancer. 5 A
HPV vaccine was implemented in 2006 as a bivalent vaccine to cover 2 genotypes, 16
and 18, and has since improved to cover 9 different genotypes. Although efficacy of the
vaccine has proven to be up to 90-100%, there are
still other carcinogenic genotypes that are not
covered by the vaccine. For this reason, screening
tests for cervical cancer are still necessary.7
Cervical cancer screening has greatly reduced
the mortality related to cervical cancer as it allows for
identification of cervical dysplasia/precursor lesions
before cancerous cells develop.8 The two different
types of tests involved in cervical cancer screening
are the Papanicolaou smear (Pap smear), which is a
cytologic test and HPV DNA testing. The Pap smear,
which was introduced to use in cervical cancer
screening in the 1950s, may involve conventional
cytology or liquid-based automated cytology.
Conventional cytology involves transferring the
collected uterine cervical sample to a slide and
interpreted by a cytotechnologist. Liquid-based

Figure 1: Bethesda System Nomenclature10

cytology (LBC) involves placing the cervical sample into a liquid to make a suspension
which will later be interpreted in a laboratory by an automated computer system.9
Cytologic abnormalities are typically described and classified according to the Bethesda
System nomenclature as described in figure 1.10 The HPV test uses molecular
technology to detect the genome of the uterine cervical cell sample. The test can be
either non-amplified or amplified, which is usually used in clinical research and includes
the hybrid capture 2 (HC2) and polymer chain reactions (PCR).2
Current guidelines recommend a screening test which includes a combination of
cervical cytology as well as HPV co-testing in women over the age of 30, with HPV
testing not recommended in women younger than the age of 30.11 The Food and Drug
Administration has approved primary HPV testing as a screening test for cervical
cancer, however this practice has not yet been adopted by the United States, possibly
due to the fear of false negative results or false positive results leading to more
unnecessary tests. However, continuing to use both methods for screening purposes
may lead to discrepant results which can be confusing for both the patient and the
provider.12 Examining the efficacy of primary HPV testing in the detection of cervical
dysplasia will also lead to decreased costs if only one test is needed for screening
purposes.
PICO
Population: females ages 21-65
Intervention: HPV screening
Comparison: screening cytology on Pap smear
Outcome: increased efficacy of diagnosis of cervical intraepithelial neoplasia
Question: Among females ages 21-65, does the use of HPV screening as compared to
cytology screening increase the efficacy of diagnosing cervical intraepithelial neoplasia?

Methods:
In September 2017, an initial Pubmed and
Scopus database search was conducted using
the key terms “HPV screening versus cytology
NOT home,” with other criteria including “within 5
years,” “full test article” and “English.” 202 articles
were found and 154 articles remained after
duplicates were excluded. Twelve of these
articles were closely screened and three were
excluded due to having little relevance to this
current study, two being simulation studies and
one was a cost analysis. Nine full-text articles
were assessed for eligibility. Six of these articles
were excluded due to the following reasons:
studies determining efficacy of HPV cotesting
rather than primary HPV screening, literature
reviews, and determining obstetrics outcomes
related to screening techniques. One
retrospective cohort and two randomized control
studies were included in this study due to the
large sample sizes, participants similar to this
study population, and these studies had
objectives to determine the efficacy of HPV
testing as primary screening as compared to
cytology. This process is displayed in figure 2.

Figure 2: PRISMA Flow Chart13
Abbreviation key: HPV- human papilloma virus, OB:
obstetric

Results:
Study 1
Human papillomavirus testing versus cytology in primary cervical cancer screening:
End-of-study and extended follow-up results from the Canadian cervical cancer
screening trial.1
Objective:
Cervical cancer screening has mostly been based on cervical cytology. However, given
the causative relationship between HPV infection and cervical carcinogenesis, this
study considers the diagnostic accuracy of HPV testing. The accuracy of detection of
CIN2+ was compared for HPV testing and cytologic testing in women participating in
primary cervical cancer screening.
Study Design:
The study is a randomized controlled trial that was conducted during the period of 2002
and 2005. Women aged 30–69 years who sought routine cervical cancer screening in
any of the 30 participating clinics in the greater Montreal area or St. John's were invited
to participate. In total n = 10,154 women were willing and eligible to enroll in the trial as

described by the inclusion and exclusion criteria in table 1. The women were then
randomized into either HPV testing or Pap cytology.

Both study groups received both screening tests for ethical reasons, however the
order in which the test were collected was randomized. This allowed maintenance of the
standard of care for the participants which allowing the study team to assess the
performance of the tests as if performed alone. The study had a blinding mechanism at
three different levels. The participating women were not aware of the study group
allocation. The cytotechnologists and cytopathologists evaluating Pap smears were
unaware of inclusion of women into the study. Comparably, colposcopists and
pathologists evaluating biopsy specimens were blinded to initial screening test results.
Each study arm had no access to test results of each other.
Pap smears were obtained and interpreted by cytotechnologist or
cytopathologists and reported according to the Bethesda System nomenclature (Figure
1). HR-HPV testing was performed using the HC2 test. Positive HR-HPV tests were
then further examined using the Linear Array HPV Genotyping Assay. Authors reported
HR-HPV genotypes as HPV+.
In the initial screening process, women who tested positive either on Pap smear
or HPV test, underwent a colposcopic exam at participating clinics. If colposcopy biopsy
specimens revealed a histologic diagnosis of CIN2+, the women were withdrawn from
the study and managed appropriately. If colposcopy revealed CIN1 or no lesion, these
patients received a repeat colposcopy in 6 months. In order to avoid verification bias,
which is a bias in testing that may occur when participants are chosen because they
have previously undergone the test of interest that is being evaluated and agree to
subsequently undergo the reference standard test, a total of 30% of patients who had
negative initial testing were selected for colposcopy.14 Women not chosen for
colposcopy were invited to receive repeat Pap smear testing at 12-18 months. This
allowed for detection of prevalent lesions as well as lesions missed at initial enrollment.
During the study, women received annual cytology as per cervical cancer screening
guidelines. Women with atypical squamous cells of undetermined significance (ASCUS)
Pap smear results received repeat Pap smear before colposcopy whereas women with
low-grade squamous intraepithelial lesion (LSIL) Pap smear result were referred
immediately for colposcopy. In 2008, HPV testing was introduced for patients over the
age of 30 and therefore guidelines changed to recommend cytologic testing every 3
years after 3 consecutive normal Pap smear results. Colposcopy referral changed to
include ASCUS HPV+ results while patients with HPV negative results were allowed to
return to routine screening protocol.

Participants from St. John's were followed up for extended period from study
enrollment date until December 31, 2013. The data on cervical cancer screening-related
procedures and their outcomes were retrieved from the provincial database for the
5,754 women in the area who participated in the trial. The reasons for extended follow
up study was the availability of well organized and comprehensive healthcare
databases in Newfoundland.
This study compared the predictive value of the Pap smear and HPV test by
using the Kaplan-Meier method which is a graphical display of survival data from a
randomized controlled trial. This method uses survival probabilities to predict time to
event in order to compare 2 groups, and log-rank test, which uses the p-value of a study
to determine if the null hypothesis can be rejected.14 Time-to-event was defined as time
from the first visit to date of first histologic diagnosis of CIN2+. HPV status was also
examined to determine predictive value of separate HPV genotypes.
Results
The average follow-up times during the protocol-defined follow-up period were
16.6 and 12.9 months for Montreal and St. John's participants, respectively. For
participants of the extended follow-up, the average time was 100 months.
In general, during the initial screening, there was more probability to test positive
on HPV than Pap smear in all study populations and regions. Among women screened
at enrollment with a valid test, it was more common to have a positive HPV test as
compared to Pap smear with 6.1% tested positive for HR-HPV and 2.9% tested Pap+
(appendix 1). Additionally, of all the women who tested HPV+ 18% of them were also
Pap+.
Throughout the initial screening and follow up, there were a total of 82 cases of
CIN2+ (median age = 36 years). The majority of cases were HPV+ as compared to
Pap+ results (82.9% versus 44.4%). This pattern was also observed in the group of
patients with discrepant test results, as there were more patients with HPV+/Pap- than
HPV-/Pap+ results (43.2% and 4.9% respectively). For the St. John's extended followup participants, additional 30 cases of CIN2+ were diagnosed, and (54.2%) were HPV+
at enrollment, whereas only 19.3% were Pap+. The HPV genotype-specific tests were
conducted using HC2 and linear array polymerase chain reaction (LA PCR). Among the
9,988 women, about 104 (1.0%) were HPV16+, 37 (0.4%) were HPV18+, 277 (2.8%)
were positive for HR-HPV types other than HPV16/18, and 64 (0.6%) were positive for
HR-HPV types not in HC2, but tested by LA PCR and 9,506 (95.2%) were HC2−
(appendix 2).
The cumulative risks for CIN2+ detection following initial screening result of
abnormal cytology or HPV testing were observed. Three year risk for CIN2+ following
high-grade squamous intraepithelial lesion (HSIL) or worse result on cytology was
significantly higher than risk associated with LSIL (p=0.02) or negative cytology
(p=<0.0001). There was also a significant difference in associated risk of LSIL result as
compared to normal cytology (p<0.0001). The three year risk of CIN2+ diagnosis for the
HPV test showed significant difference between the HPV+ and the HPV- groups
(p<0.0001). These results are displayed in figure 3. Risk associated with Pap+/HPV+
was significantly higher than discrepant test results (35.77% versus 8.96% HPV+/Pap-

and 2.73% HPV-/Pap+), and abnormal cytology helped to further stratify risk in those
patient with HPV+ result.
During the extended follow-up period, risks, associated with results of either Pap
cytology or HPV testing at initial screening had a trend similar to those of protocoldefined period. However, there were no significant differences in risks between women
with HSIL versus LSIL Pap cytology. Overall, 10-year cumulative detection of CIN2+
ranged from 1.15% for HPV−/Pap− women to 26.05% for HPV+/Pap+ women (appendix
3).
Genotype specific results were also observed and showed a dramatic increased
risk for patients with HPV16+ result as compared to HPV+ result with genotyping other
than 16/18 (p=<0.001). There was no significant difference in HPV16+ versus HPV18+
results (p=0.19). The three year risk associated with HPV16+ was 43.84% as compared
to 0.90% for patient with HC2- results. These estimates of risk were higher than those
associated with Pap+ or HPV+ results. Extended follow-up results of 10 year risk
associated with HPV genotyping results were again similar to the protocol-driven followup results, with risk associated with HC2- at 1.13% as compared to HPV16+ at
32.78%.

Figure 3: Risk for CIN2+ is portrayed on y-axis as percent of patients with CIN2+ diagnosis while the xaxis represents time.1
Figure 3a shows risk for CIN2+ diagnosis during protocol-defined follow-up period associated with results
of Pap cytology. Figure 3b shows risk for CIN2+ diagnosis during protocol-defined follow-up period
associated with results of HPV testing.
Abbreviations: CIN: cervical intraepithelial neoplasia, Pap: Papanicolaou

Study critique:
This study tried to address the perceived advantage of HPV testing over Pap
smear in primary screening of cervical cancer, and the authors have done a good job in
trying to quantify a measurable outcome. However, the validity HPV genotyping in
predicting development of cervical cancer and guiding medical management of women
with HR-HPV+ but normal cytology results the data is inconclusive. The reason is that,
although the utilization of genotyping has the potential for identifying the high risk
genotypes and improve the way we manage the patients with HR-HPV+, availability
statistical data is still limited. The authors of the study recommended larger scale study.

Another concern with this study is the practicality of the testing methods they
used. In the study population, the standard screening procedure is for women with
HPV− and Pap− results in no further colposcopy testing is recommended. However, in
the study to correct for verification bias they standardized colposcopy protocol, thereby
increasing the chances of detecting CIN2+ and decrease the chances of finding
cancerous lesions later in the lives of these women (because the early detection of
abnormal lesions by colposcopy). Therefore, their recommendations should be taken
with a little bit of caution, and the authors address this in their discussion.
Finally, the study was conducted in the Canadian population with some
similarities to the US population in terms of geographical proximity and possibly the
population composition. For this reason, the results of the study may be applicable to
the US patients. However, it is important to note that the healthcare system is different
in terms of availability and continuity between these two countries. As an example, in
the above-mentioned study population, health care is government mandated and they
had an ample access to health care. As a result, relatively extensive medical records
were available for the study. In comparison, the availability of healthcare coverage in
the US is not comparable to that of Canada’s. Therefore, the conclusion of the study
should be taken with some caution.

Study 2
Cervical screening with primary HPV testing or cytology in a population of women in
which those aged 33 years or younger had previously been offered HPV vaccination:
Results of Compass pilot trial randomised control.15
Objective:
Most studies about efficacy primary HPV testing for cervical screening in
comparison to the traditional cytology (Pap smear) have been on populations with little
or no previous access to HPV vaccination. Therefore, this study is done to assess the
improved performance of primary HPV testing for cervical screening in detection of
high-grade cervical intraepithelial neoplastic lesions (defined as CIN2+) and invasive
cancer as compared to cytology (Pap smear) in a population previously offered HPV
vaccination.
Study Design:
The Compass is an open-label randomized trial of 5-yearly HPV screening that
consisted two-arms versus 2.5-yearly liquid-based cytology (LBC) screening. An openlabel randomized trial means the clinical trial was conducted without an attempt to
disguise the treatment/ screening options and therefore the researchers and the
patients were aware of the type of screening they received. A total of 5,006 eligible
women (as described in Table 2) were recruited from 29 October 2013 to 7 November
2014; of these, 22% were in the group age-eligible for vaccination that is women <30
years of age.

Initially, consenting women aged 25–64 years presenting for routine screening at
47 primary practices in Victoria, Australia were included in the study and a cervical
sample was collected. The samples were then randomized at a central laboratory at 1 to
2 to 2 ratio allocations to the three arms of the study: (i) image-read LBC screening with
HPV triage of low-grade cytology (‘LBC screening’), (ii) HPV screening with those
HPV16/18 positive referred to colposcopy and with LBC triage for other oncogenic or
other ‘high risk’ (OHR) types (‘HPV+LBC triage’), or (iii) HPV screening with those
HPV16/18 positive referred to colposcopy and with dual-stained (DS) cytology triage for
OHR types (‘HPV+DS triage’). In other words for every one patient assigned to the LBC
screening, two patients each were assigned to ‘HPV+LBC triage’, and to ‘HPV+DS
triage.’ Study groups and management for each group are shown in figure 4.
The initial recruitment process employed two-tier blinding and randomization: the
participating women and recruiting personnel were blinded to randomization
assignment. Then, following the receipt of the LBC sample at the centralized laboratory,
participants were randomized based on a computer-generated schedule.
The computer-generated schedule was an independent design by the Australian
government National Health and Medical Research (NHMRC) Clinical Trials Centre at
the University of Sydney. Furthermore, the randomization used a minimization
procedure stratified by age group <30 and 30+ years; in order to try to stratify those
patients who likely received HPV vaccination. This was meant to ensure a good balance
between the three arms across the stratification levels, as well as overall. Laboratory
personnel were only made aware of the study groups after receipt and proper logging of
each sample in order to maintain blinding.
ThinPrep cytology was used for LBC and the 2 methods for HPV screening
included HC2 for 22% of participants and Cobas for the initial 78% of participants. For
dual-stained cytology testing, CINtec PLUS technology was used, which stains for the
markers p16 and Ki67. Australian screening recommendation for cervical cancer
screening were followed and included cytology every 3 years and HPV screening every
5 years. In order to correct a potential verification bias a proportion (16%) of all women
not referred to colposcopy were randomly selected and invited for verification
colposcopy performed at the Royal Women’s Hospital, Melbourne. However, the
participation of rate of the women invited was very low to be a representative of an
impartial sample.
Statistical analysis of all eligible participants (minus the withdrawals) was done
using Mantel–Haenszel test, a statistical significance test analysis where the null
hypothesis states that no difference exists between the overall life table results for the

study and control group.14 This test compared the colposcopy referral rates and CIN2+
detection rates in the LBC screening arm with those in the combined HPV screening
arms, and between the two HPV screening arms (HPV+LBC triage, and HPV+DS
triage).
Results:
Of the total number of 5,303 participants initially recruited, 297 women were
ineligible and excluded from the study. 5,006 participants were randomized to the
different study arms. 998 were assigned to LBC screening, with 3 withdrawing before
analysis. 1,996 were assigned to arm 2 of the study and 4 participants withdrew before
analysis. Finally, 2,012 participants were assigned to the third study arm, with 4
participants withdrawing before analysis. Therefore, data was collected on a total of
4,995 participants. The randomization of the study participants is described in Table 3.
Table 3: Case numbers and rates of detected CIN2+

The final results were classified by the initial observed high-grade cytology rate,
colposcopy referral rate, overall confirmed CIN2+ and CIN3+ rates in each group, and
the overall colposcopy referral rate and detected CIN2+ rate (including 12-month followup) in young women previously age-eligible for vaccination, and older women (ageineligible for vaccination).
As the numbers of detections increased so did the numbers of colposcopy
referral rate. The referral rates were classified into those referred based on the primary
screening test, a positive triage test, or those detected at 12-month follow-up. Overall
181 women were referred for colposcopy and histologic outcomes were available for
177 of these participants. However, there was no clinical significance found between
referral rates of LBC screened participants as compared to all HPV screened
participants (referral rates displayed in figure 4). Also, after 12 months there was no
clinical significance in referral rate of the 2 different kinds of HPV testing. There was,
however, clinical significance when compared to historical data of colposcopy referral
rates in Victoria in 2013. LBC referral rates were significantly lower than this reference
rate (p=0.02) and the HPV+DS referral rate was significantly higher (p=<0.001).

Referral rate for colposcopy by screening group
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Figure 4: Referral rate for colposcopy in Study 2
y-axis: percent of patients in each screening group referred for colposcopy; x-axis: different basis
for referral. Abbreviations: HPV: Human Papillomavirus, LBC: liquid based cytology; DS: dualstained

In the initial screening, the observed percentage of high-grade cytology was
0.1% in LBC screening group. The rate of detection then jumps by 13x to 1.3% of
participants were HPV16/18 positive in the HPV+LBC triage group. The overall
confirmed CIN2+ rates in each group, LBC screening, HPV+LBC triage, and HPV+DS
triage groups, were 0.2%, 1.7%, and 2%, respectively. This shows that it is 10x more
likely to detect CIN2+ rates by HPV-screened women combined than the LBCscreened, but no significant difference was identified between overall CIN2+ rates in the
2 HPV-screened groups after adjusting for HPV vaccination eligibility. The overall
colposcopy referral rate and detected CIN2+ rate (including 12-month follow-up) is
higher in the HPV-screened women than in the LBC screened.
The overall CIN2+ and CIN3+ rates in each colposcopy referred group was
observed to determine the accuracy of referral for each test. There was a significant
difference identified between the CIN2+ rates in the LBC-screened versus all HPVscreened patients (p=0.003). On the other hand, there was no clinical significance found
in CIN2+ diagnosis in the 2 HPV-screened groups. These results are displayed in figure
5 below.

Rates of detected CIN2+ after colposcopy
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Figure 5: CIN2+ result rates after colposcopy in Study 2
y-axis: percent of patients with positive CIN2+ after colposcopy referral. x-axis: different study groups as
defined as possible HPV vaccination or no HPV vaccination and total CIN2+ result. Abbreviations: HPV:
human papillomavirus, LBC: liquid based cytology; CIN: cervical intraepithelial neoplasia DS: dual-stained

During the follow up for adverse events a total of four deaths were reported, two
deaths from each HPV+LBC, and HPV+DS triage groups. These events were reviewed
by the trial Independent Data and Safety Monitoring Committee (IDSMC), and ruled out
as unrelated to the trial. Additional two adverse events, one each from LBC screening
group & the HPV+LBC triage group. These were miscommunication issues involving
screening results, rather than related to clinical findings.
Study critique:
This study is very applicable as one of the first studies examining efficacy of
different cervical cancer screening methods to include a highly HPV vaccinated
population. The study tried to incorporate a population with similar demographics to
those presenting for cervical cancer screening, however it was noted that this study
contained a smaller percent of patients in the 25-29 age group as compared to reported
screening demographics for Australia. This may be important when considering the
clinical application of these results as this age group may represent a large number of
women who have received the HPV vaccine.
Researchers also tried to consider the possibility of HPV vaccination during the
randomization into the different arms of the study as it included similar percentage of
women offered HPV vaccination into each arm. This allowed for the study to also
determine accuracy rates in patients offered vaccination. However, the study could only
determine possibility of vaccination based on the patient’s age since vaccination status
of each patient was not provided.
A low rate of CIN was detected by LBC as compared to previously reported rates
in 2013. This prompted researchers to re-read each result through an outside laboratory
to make sure there were no errors in diagnosis. There was also a significantly high rate
of CIN in the HPV+DS group. Researchers recommended caution when comparing

these rates to the historical data as this study did not include any women who are under
surveillance for previous abnormal results but rather includes a population of wellscreened women. Therefore, this may limit the application to the general population.
Finally, this study focused on positive predictive value of initial tests after the
referral to colposcopy. Positive predictive value meaning the proportion of individuals
with a positive test who actually have the disease as measured by the reference
standard. This is the probability of having an abnormal diagnostic test if the screening
test is positive.14 This only included 181 patients and does not address the accuracy of
the screening test in terms of false-negative results that would therefore not be referred
to colposcopy.
Study 3
Discrepant HPV/Cytology Cotesting Results: Are There Differences Between CytologyNegative Versus HPV-Negative Cervical Intraepithelial Neoplasia?12
Study Objective
To compare characteristics of HSIL (specifically categorized as CIN3+) after
negative cytology but positive HR-HPV (negative for intraepithelial lesion or malignancy
[NILM]/HPV-positive) with characteristics of HSILs after negative HR-HPV but positive
cytology (ASCUS positive/HPV negative). The reason for these discrepancies was
explored to further characterize and understand the occurrence of these false positive
tests.
Study Design
This is a retrospective cohort study in which results were retrieved through a
computer-based search using Cerner Millennium health information system (Kansas
City, Kansas) for women who underwent both LBC screening and HPV testing from
January 2010 through December 2013. This included 15,173 women ages 25-99.
ThinPrep Pap test specimens were prepared and initially interpreted by
cytotechnologists and pathologist and then independent retrospective review was
performed by 2 pathologists who were blinded to both the initial cytologic diagnosis as
well as the surgical pathological diagnosis. HPV testing included reflex HPV testing,
HPV cotesting for women over 30 years old or HPV tests that were requested for
patients under 30 years old for unknown reasons. This testing was performed in
residual PreservCyt vials using the Cobas 4800 system which tests for HPV types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. The results of this HPV test is
reported as either positive or negative with further characterization of the specific
subtypes in test that are HR-HPV positive.
Histopathologic diagnosis of HSIL, specifically categorized as CIN3+, was made
on hematoxylin and eosin-stained histopathologic specimens from endocervical
curettage, biopsy, loop electrosurgical excision of the uterine cervix and hysterectomies.
Again, an independent retrospective review by 2 pathologists was used to confirm the
original diagnosis. Immunohistochemical analysis evaluated for the expression of p16 in
formalin-fixed, paraffin-embedded cervical biopsy specimens using CINtec cyclindependent kinase inhibitor 4A histology kit and an automated Ventana BenchMark

ULTRA system. Results were defined as positive with the presence of both cytoplasmic
and nuclear staining.
Statistical analysis was performed using the XLSTAT and SPSS software by
analyzing both variance and chi-square tests for clinical and pathologic features and
were considered significant at P<0.05.
Results
Of the 15,173 women screened with both Pap smear and HR-HPV, 2,944 women
had a cytologic finding of ASCUS or greater. Within this group of women with abnormal
cytology, 2,200 women tested positive for one of the HR-HPV subtypes. 1,184 of these
women had histopathologic follow up and a total of 84 of these women had CIN3
positive results. 55 patients tested ASCUS-positive/HPV-positive, 11 tested
NILM/HPV+, 10 tested ASCUS-positive/HPV-, 3 tested NILM/HPV-, and 5 tested
unsatisfactory.
Table 4: Clinical parameters measured and results for Study 3

Clinical and pathologic parameters were investigated for the 24 patients who had
discrepant cytology/HPV results as displayed in table 4. These parameters included
patient age, patient race, history of screening, time to diagnosis, lesion size and
presence of viral cytopathic changes. Each of these parameters were examined for
each group individually and then compared overall.
Cytology-positive/HPVTen patients with CIN3+ histology had positive cytology with negative HPV
screening. The clinical parameters observed are shown in table 4. On review of
pathology, one patient was excluded due to unavailability of the initial biopsy for review.
Two women from this result group were diagnosed endometrial cancers extending into
the cervix and therefore were excluded from further discussion. The remaining 7
patients were examined and the average age, lesion size and time to occurrence were
documented as provided in table 4.
NILM/HPV+
Eleven patients had normal cytology with positive HPV co-testing. The clinical
parameters for these patients are displayed in table 4. Upon review of cytology, six of

the screening cytology results were reclassified as ASCUS, and this was attributed to
interpreter error. The five other patient results remained classified as NILM and were
attributed to cytologic sampling error.
NILM/HPVThree women had CIN3+ on histology after NILM/HPV- screening. Clinical
parameters for these patients are discussed in table. After pathological review, there
was no reclassification of cytology or pathologic results. One patient, who presented
initially with postmenopausal bleeding, was diagnosed with endometrial
adenocarcinoma.
There was no significance detected in the clinical or pathologic features in the
patients diagnosed with CIN3+ who had NILM/HPV+ or Cytology+ /HPV- Pap smear
results.
Study Critique
This study is a retrospective cohort study. This is an observational study design
in which participants in the study are enrolled and studied after the outcome which is
being observed has already occurred.14 For this study specifically, investigators
reviewed the medical records of patients that met criteria for the study after the Pap
smears and HPV testing were already performed. They reviewed the results of these
tests after the outcome already occurred. Confounding variables, which are differences
in the different study groups that could potentially affect the outcome, were minimized
by having specific inclusion and exclusion criteria for the study participants. However,
not all confounding variables can be addressed in these studying which remains a
disadvantage of this study design. Since the outcomes of this study has already
occurred there may be some confounding variables of which the researchers were not
aware at the time they were reviewing these patient records.
This type of study is beneficial for the objectives of the study because it is an
observational study, meaning researchers are observing data rather than using any
interventions in the study groups. The objective of this study, to compare accuracy of
screening tests, does not need any type of specific intervention as investigators are
observing the results of the two screening tests and the accuracy in predicting abnormal
diagnostic testing. This type of study is beneficial in terms of the study’s objectives
because researchers are able to look at previous records and record incidence of
abnormal Pap smear results or HPV test result after patients had an abnormal follow up
diagnostic test.
Although this study initially began with a very large sample size of 15,173 women
receiving cervical cancer screening, only 24 of those patients had discrepant cytology
and HPV screening results and therefore the sample size discussed in this study was
very small. The authors do address this issue during the discussion and state that this
small sample size may be responsible for their results being different than previous
studies, for example other studies that noted age as a possible explanation for
discrepancy in screening test results. The inclusion and exclusion criteria for this study
was not clearly discussed or displayed in the study, which may lead to confusion
regarding the non-squamous cell cancer results that were later excluded from the study.

There is also one patient that was discussed in the NILM/HPV- group that had the Pap
smear with HPV co-testing performed as part of her workup for postmenopausal
bleeding. This means that the testing is no longer considered a screening test and
should not have been included in a study examining the use of HPV as a screening test.
The discussion of the study did address possible explanations for discrepant
results by referring to conclusion from other studies, including low residual volume of
the sample for the HPV testing as well as the possibility of the specific subtype of HPV
not being screened in those discrepant cases. This enhances the analysis of this study
and may give direction to future studies that may address these issues. The authors
also addressed other limitations to their study, including possible bias regarding
cytologic and pathologic review since the interpreters were aware of the CIN3+ end
point. The authors also noted that only by including CIN3+ results in the study may miss
many other discrepant results for patients with CIN2 and CIN1 results. Acknowledging
these limitations may allow for better future studies regarding these screening tests.
Discussion
Three studies were chosen for review in order to examine the efficacy of primary
HPV testing as compared to cytologic testing as screening tests for cervical
intraepithelial neoplasia. Overviews of each of these studies are displayed in table 5.
The first two studies were applicable to our clinical question as they examined the
efficacy of HPV testing as compared to cytology in different populations. The third study
explored possible clinical or pathologic features that may contribute to discrepant
screening results. Better understanding of possible etiologies of these discrepant results
in screening tests may allow for more individualized screening methods in certain
populations. More accurate screening tests may lead to increased efficiency of
screening protocols and will limit the extent of screening and diagnostic tests necessary
for diagnosis of precancerous and cancerous lesions.
Table 5: Overview of Studies
Study 1
Isidean et. al

Study 2
Canfell et. al

Study 3
Tracht et. al

Objective

To compare the
performance of HPV
testing and Pap cytology
in detecting CIN2+ for
patients following routine
cervical cancer screening
in Canada

To estimate the test
positivity rate (colposcopy
referral rate) and CIN2+
detection rates for HPVscreened versus cytologyscreened women in
Australia’s HPVvaccinated population

To compare
characteristics of CIN3
diagnosed after negative
cytology but positive HRHPV with characteristics
of CIN3 diagnosed after
negative HR-HPV but
positive cytology

Study Design

Randomized control trial

Randomized control trial

Retrospective cohort

Patients (n)

10,154

5,000

15,173

Population age

30-69

25-64

25-99

12-16 months; extended
follow up of 100 months

13 months

36 months

CIN2+

CIN2+

CIN3

Follow up period
Outcome

Conclusion

HPV-based cervical
screening may allow for
greater disease detection
than cytology based
screening

Critique

Increased rates of CIN2+
detection by using a
verification protocol to
include some of screening
group who may not have
been referred to
colposcopy based on
screening protocol

Primary HPV testing
provided significantly
increased detection of
high grade precancerous
lesion as compared to
cytology in patients with
high rates of HPV
vaccination
Vaccinations status of
participants not recorded,
assessed possibility of
vaccination based on age

There are no significant
clinical or pathologic
differences between
discrepant cytology and
HPV testing results and
HPV-/cytology+ results
may be missed with
primary HPV screening
Large sample size initially
but discrepant results
from that sample only
included 24 patients

The studies show the superior specificity of HPV testing as compared to Pap
smear in detecting CIN2+ or worse after colposcopy referral. The first study also
showed that the precision of predicting 5-year risks for HPV− women was higher than 3year risks for Pap- women, and was comparable to 5-year risks for co-test negative
women. Therefore, if primary HPV testing is incorporated into cervical screening
protocols then there may be increased accuracy of the screening tests which will allow
for more favorable screening intervals and reduced cost. However, referral to
colposcopy for this study was based on the co-test result and therefore may not be
representative of primary HPV colposcopy referrals. The inclusion of normal screening
participants in the colposcopy group may have lead to a greater detection rate of CIN2+
lesions that would have been missed if primary HPV testing or cytology testing were
performed alone.
With increased rates of HPV vaccination in the United States, the second study
may be very applicable to determine the efficacy of HPV screening as compared to
cytology in this population. This study showed more accurate rates of diagnosing CIN2+
in those patients that have been referred for colposcopy which may allow for earlier
treatment and prevention of advancement of the lesion. As stated in the study, this has
been examined in previous studies however this is the first study to include a highly
HPV vaccinated population. This study also examined predictive value of HPV genotype
testing which may be used in initial screening in order to recommend colposcopy initially
rather than requiring cytology follow up. As compared to previous studies, this study
found lower rates of high risk HPV infection in this HPV vaccinated population which
also supports the use of HPV vaccination to prevent not only cervical cancer but also
unnecessary colposcopy testing.
The final study looked to investigate possible clinical or pathologic features for
discrepant cytologic and HPV testing results with later diagnosis of CIN. This study
concluded that the most common causes of discrepant results were interpretation error,
sampling error, HPV infection with subtype not currently screened or neoplasia due to
non-HPV related carcinoma. The study found no clinical significance in the clinical
characteristics of the patients or pathologic parameters of the diagnosis to distinguish
which patients may present with these discrepant results. In this study, cytologypositive/HPV-negative accounts for 29% of discrepant results in screening tests. Since

there were no additional clinical parameters to help determine which patients may have
discrepant HPV or cytology results, using HPV testing as a primary screening test may
lead to missed diagnoses of these neoplasms that are either non-HPV related or
subtypes that are not specifically tested.
Conclusion
Primary HPV testing may increase accuracy of referral for colposcopy and
therefore CIN2+ diagnoses as compared to cytology. However, these conclusions are
based on diagnosis rates after colposcopy referral and therefore do not address
possible false-negative screening results in patients who have non-HPV related lesions
at the time of screening. Currently, there are also no clinical or pathologic features that
may guide clinicians in determining which patients may present with false-negative
screening results. Due to the lack of identified risk factors that may help predict falsenegative results, the authors of this study do not recommend the use of HPV testing
alone. Further study can focus on addressing this group of patients that may present
with false-negative HPV results at the time of screening.
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Appendix
Appendix 1: Case numbers and rates for detected CIN2+ and CIN3+, by age
eligibility for vaccination.
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Appendix 2: Positive predictive values for CIN2+ and CIN3+, by allocation group
and referral pathway.
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Appendix 3: Estimated colposcopy referral rates by study group.
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